Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2012 1
2018 1
2021 4
2022 5
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, Zisapel M, Elalouf O, Kaufman I, Meidan R, Broyde A, Polachek A, Wollman J, Litinsky I, Meridor K, Nochomovitz H, Silberman A, Rosenberg D, Feld J, Haddad A, Gazzit T, Elias M, Higazi N, Kharouf F, Shefer G, Sharon O, Pel S, Nevo S, Elkayam O. Furer V, et al. Among authors: pel s. Ann Rheum Dis. 2021 Oct;80(10):1330-1338. doi: 10.1136/annrheumdis-2021-220647. Epub 2021 Jun 14. Ann Rheum Dis. 2021. PMID: 34127481
Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study.
Furer V, Eviatar T, Freund T, Peleg H, Paran D, Levartovsky D, Kaufman I, Broyde A, Elalouf O, Polachek A, Feld J, Haddad A, Gazitt T, Elias M, Higazi N, Kharouf F, Gertel S, Pel S, Nevo S, Hagin D, Zisman D, Elkayam O. Furer V, et al. Among authors: pel s. Ann Rheum Dis. 2022 Nov;81(11):1594-1602. doi: 10.1136/ard-2022-222550. Epub 2022 Jul 22. Ann Rheum Dis. 2022. PMID: 35868846
Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications.
Heshin-Bekenstein M, Ziv A, Toplak N, Hagin D, Kadishevich D, Butbul YA, Saiag E, Kaufman A, Shefer G, Sharon O, Pel S, Elkayam O, Uziel Y. Heshin-Bekenstein M, et al. Among authors: pel s. Rheumatology (Oxford). 2022 Nov 2;61(11):4263-4272. doi: 10.1093/rheumatology/keac103. Rheumatology (Oxford). 2022. PMID: 35179569 Free PMC article.
Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab.
Furer V, Eviatar T, Zisman D, Peleg H, Braun-Moscovici Y, Balbir-Gurman A, Paran D, Levartovsky D, Zisapel M, Elalouf O, Kaufman I, Broyde A, Polachek A, Feld J, Haddad A, Gazitt T, Elias M, Higazi N, Kharouf F, Pel S, Nevo S, Elkayam O. Furer V, et al. Among authors: pel s. Vaccines (Basel). 2022 Jun 6;10(6):901. doi: 10.3390/vaccines10060901. Vaccines (Basel). 2022. PMID: 35746508 Free PMC article.
Effect of Secukinumab and Tumor Necrosis Factor Inhibitors on Humoral Response to BNT162b2 mRNA Vaccine in Patients With Spondyloarthritis Compared to Immunocompetent Controls.
Eviatar T, Furer V, Polachek A, Zisman D, Peleg H, Elalouf O, Levartovsky D, Kaufman I, Broyde A, Haddad A, Feld J, Aassi M, Quebe-Fehling E, Alarcon I, Pel S, Paran D, Elkayam O. Eviatar T, et al. Among authors: pel s. J Rheumatol. 2023 Nov 1:jrheum.2023-0357. doi: 10.3899/jrheum.2023-0357. Online ahead of print. J Rheumatol. 2023. PMID: 37914221 Free article.
Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study.
Heshin-Bekenstein M, Ziv A, Toplak N, Lazauskas S, Kadishevich D, Ben-Nun Yaari E, Miller-Barmak A, Butbul Aviel Y, Saiag E, Pel S, Elkayam O, Uziel Y, Furer V. Heshin-Bekenstein M, et al. Among authors: pel s. Vaccines (Basel). 2023 Apr 10;11(4):819. doi: 10.3390/vaccines11040819. Vaccines (Basel). 2023. PMID: 37112731 Free PMC article.
14 results